Anthropic CRISPR Controversy: What Has Happened So Far 

Within 21 hours, about 950 AI agents searched through a vast library of DNA sequences and found a pattern Anthropic described as previously uncharacterized. The company announced the finding on 23 September 2026, and the Anthropic CRISPR controversy began. Some voices raised it as momentous, while others called the find a modest step and an overhyped start of the race. Shortly afterward, a University of Copenhagen researcher said that his own, yet unpublished research described the same patterns.

Gene-editing companies’ stocks fluctuated, Twitter users debated, and, in general, many people questioned what exactly has been discovered. This article reiterates the main facts of the controversy to provide context for the debate. It also comments on why this finding is compared to CRISPR, who has expressed any disagreement, and what the prospects are in this regard.

What Has Anthropic Actually Discovered?

Anthropic announced the opening of a new life sciences research laboratory and revealed the results of its first investigations. Its Claude AI agents identified an enzyme system associated with an array of regularly spaced DNA repeats, similar in some structural respects to CRISPR.

The company has proposed to call this system ART (array-associated reverse transcriptases) – a designation used in its announcement. According to the announcement, ART is found in bacteriophages – viruses that infect the bacteria – and includes three key elements – a reverse transcriptase enzyme, the neighboring gene, and a DNA array.

Several terms need clarification here: RT is an enzyme that synthesizes DNA molecules from RNA, bacteriophages are viruses that infect bacteria, and DNA repeat arrays are regions of DNA containing repeated sequence units, sometimes separated by intervening sequences. However, despite the similarities, ART is not a proved gene-editing tool; this system seems to have a biological function that remains unknown.

How Could Claude Discover Something so Coincidental?

Anthropic emphasized that the scientists who created the prompt for Claude AI participated in the initial stage of the computational search and performed the laboratory work. The agents worked on the task simultaneously in parallel threads, searching for the most promising candidates among the existing data sets. The following numbers illustrate the scale of this process:

Source: Anthropic’s announcement on 23 September 2026.

In addition to the obvious conclusion about the impressive scale of Claude AI’s computational work, one can also note that the process narrowed thousands of candidate systems to 20 particularly promising candidates in a workflow that included a 21-hour computational search. These figures are reported by Anthropic and do not independently establish the accuracy or scientific importance of the selected candidates. The company describes the 20 candidates as particularly compelling, rather than as 20 validated discoveries. This speed, however, cannot be decisive in the debate on the merits of the discovery.

Also Read: Artificial Intelligence Archives – SA News

Why Was It Compared to CRISPR?

In order to understand the controversy, it is essential to distinguish what CRISPR technology is, what purposes it serves, and what functions ART actually has. First of all, CRISPR-Cas9 is a gene-editing tool derived from a bacterial defense mechanism against viruses. More specifically, the guide RNA binds to a complementary DNA target and directs the Cas9 enzyme, which acts like scissors, to cut it. Thus, scientists can target particular nucleotide sequences in the genome with a high degree of precision, subject to the system’s sequence requirements.

The first CRISPR-based therapy, the drug Casgevy, received regulatory approval from the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) on 16 November 2023. Therefore, CRISPR is not a futuristic concept but a working technology that has demonstrated clinical benefit in specific approved indications. The similarity between ART and CRISPR lies in the fact that both systems are associated with DNA repeat arrays.

According to preliminary findings reported by Anthropic, the ART array is expressed as distinct short RNA molecules. Whether these RNAs function as guide strands like those in CRISPR remains unknown. This comparison, however, barely goes beyond a structural resemblance and a possible functional hypothesis, and the main issue of the controversy lies in other arguments.

Why Did Gene-Editing Stocks Lose Value?

The day of the announcement, several companies’ stocks fell sharply in value. More specifically, on Wednesday, 23 September 2026, CRISPR Therapeutics dropped by approximately 6%, Beam – by 6%, Intellia – by 3%, Prime Medicine – by 12%, and Editas – by 8%, according to market reports. The declines were reported amid speculation that an AI research laboratory could eventually compete with gene-editing companies in the development of therapies. However, the timing of the declines does not establish that the announcement alone caused the price movements or that all investors shared this concern.

Some commentators responded to this concern by noting that the discovery does not, by itself, challenge the existing use of CRISPR-based treatments. At the same time, the preliminary nature of the finding provides no guarantee of practical applications in the near future. Any specific prediction about the future of existing CRISPR therapies should be attributed to a named analyst and supported by the original report.

In any case, this reaction of capital markets demonstrates that scientific findings can be interpreted in ways that may not be justified by the available evidence. Biotechnology companies continue to invest enormous sums in research and development, and years of clinical trials and safety assessments may lie ahead for any new enzyme intended for therapeutic use.

Anthropic CRISPR Controversy: Who Actually Discovered It First?

One of the strongest challenges to Anthropic’s claims came from Mario Rodríguez Mestre, a University of Copenhagen researcher. Shortly after the announcement, he told reporters that his unpublished doctoral research described related patterns in viral DNA. According to his account, his group had been studying the relevant enzymes and associated molecules for years, and he had shared research-related information with Anthropic’s AI models.

This raises questions about scientific priority and the possible influence of previously shared information, but it does not by itself establish that the two research efforts were identical in scope or that one directly influenced the other.

Mestre told CNN via email that “It is essentially the same finding. This is not simply a case of two groups studying related protein families or similar biological systems.”

It is noteworthy that Mestre described his research as unpublished, meaning that it had not yet been formally published in a scientific journal. However, unpublished research can still predate another discovery; its publication status does not, by itself, settle questions of scientific priority. The key questions are what the earlier research had established, when it had established it, and what documentary evidence supports those claims.

According to the researcher, there are several possible explanations for why Anthropic’s AI could have identified ART: the model may have encountered relevant information through some route, or the result may have been independently rediscovered with more human direction than the company acknowledged. Mestre raised concerns about information he had shared with Claude.

However, the available reporting does not establish that his data entered the model’s training set or influenced the particular result. Anthropic has said that the model responsible for the discovery was not trained on user transcripts.

Mestre stated that the more plausible possibility, in his view, was that “there was considerably more prior scientific knowledge and human direction behind the search than the phrase ‘autonomous discovery’ suggests.” He also indicated that his group had been studying the relevant system as early as 2022. However, the validity and precise scope of this priority claim remain unproved for now, as the available public evidence does not conclusively establish what his group had identified at each stage or how the two research efforts relate.

That is why the controversy between Mestre and Anthropic is not only interesting but also significant. The fact is that the role of humans in the work of AI may be much greater than it seems. As the outcome of this debate becomes clearer, it may be possible to assess more precisely how the discovery should be attributed to AI and human researchers.

What Do Independent Researchers Say About ART?

Outside of the controversy, it is also essential to assess the opinions of independent researchers. Aaron Engelhart of the University of Minnesota is among the researchers whose views on the findings have been discussed. The results reported by Anthropic are potentially interesting and worthy of further investigation.

At the same time, the findings remain at a preliminary stage of research, and the biological function of ART has not yet been established.

Some independent scientists also voiced similar reservations, noting that the discovery’s practical significance remains uncertain and that its long-term importance cannot yet be established.

Also Read: The Hidden Cost of AI: Why Communities Are Fighting Data Centers

Anthropic’s own statements on the subject are also cautious. The company makes its findings available as a preprint, while Nature has published news coverage of the discovery. Anthropic notes that the underlying reverse transcriptase was already known, while the proposed advance concerns the association of this enzyme with a DNA array and an additional gene product. The importance of this association remains to be established through further research.

What Has Been Proven and What Has Not: Summary Table

From the above information, one can extract the essential points of the controversy and the facts that have been established or reported so far. The following table presents this information in a structured manner.

Sources: Anthropic, Nature, bioRxiv, and other above-mentioned reports

A similar situation is typical of many scientific discoveries: initially, only a few researchers share information about them, while the general public often speculates about their significance. In this regard, it is too early to call ART revolutionary or overhyped.

What Are the Prospects of This Discovery?

The prospects for this scientific finding can be considered from three perspectives: laboratory experiments, peer review, and ethical and legal issues. Firstly, Anthropic says that research into ART’s primary function is ongoing. Researchers will need to conduct further experiments to reveal the system’s properties and determine whether it has practical applications in biotechnology and gene editing.

Secondly, the research manuscript is available as a preprint, allowing other researchers to examine the reported findings. Peer review, if completed, could help assess the quality of the work, but it would not automatically settle questions of scientific priority or establish practical utility. In particular, the experiments described in the study should be reproducible and may be subject to additional scrutiny. Thirdly, the controversy between Mestre and Anthropic raises potential ethical and legal questions. Resolving these issues may require clarification of research-data provenance, confidentiality and attribution, although no legal violation or outcome has been established by the information discussed here.

What Can We Learn from the Anthropic CRISPR Controversy?

The most valuable lesson from this story is probably that a comparison with CRISPR can invite speculation but rarely establishes revolutionary significance. Moreover, this episode demonstrates that discoveries in biology and genetics can attract excessive hype, which, however, does not necessarily correlate with their eventual practical value. In fact, years of research and clinical trials may lie behind every new gene-editing treatment intended for human use, and many potential treatments fail during development or clinical testing.

People are often unprepared for this slowness and the associated uncertainty. For this reason, many people turn to faith, asking higher powers to answer the big questions of life. One such spiritual leader is Saint Rampal Ji Maharaj, who has been advocating for humanity to seek the wisdom of the Supreme Soul. His books “Gyan Ganga” and “Way of Living” are presented by his followers as discourses on the subject, offering spiritual perspectives on questions that may be burning in your heart.

Frequently Asked Questions (FAQs)

1. What is the Anthropic CRISPR controversy?

The Anthropic CRISPR controversy began on 23 September 2026, when Anthropic announced that its Claude AI agents had identified a previously uncharacterized biological system called ART (array-associated reverse transcriptases). The finding attracted attention because of its structural similarities to CRISPR, raising questions about its scientific significance, potential applications, and the role of AI in biological research.

2. What has Anthropic’s Claude AI discovered?

Anthropic reported that approximately 950 Claude AI agents searched DNA sequence data for 21 hours, processing around 210 million tokens and examining more than 200,000 reverse transcriptases. The system identified candidate enzyme systems associated with DNA repeat arrays and neighboring genes. However, ART’s biological function remains unknown, and it has not been established as a gene-editing technology.

3. How is ART different from CRISPR?

CRISPR-Cas9 is an established gene-editing technology that uses guide RNA to direct an enzyme to a specific DNA sequence for cutting. ART shares certain structural features with CRISPR, including an association with DNA repeat arrays, but its function is still being investigated. There is currently insufficient evidence to conclude that ART can edit genes or serve as an alternative to CRISPR-based treatments.

4. Why did gene-editing companies’ stocks fall after Anthropic’s announcement?

On 23 September 2026, several gene-editing companies, including CRISPR Therapeutics, Beam Therapeutics, Intellia Therapeutics, Prime Medicine, and Editas Medicine, reportedly experienced share-price declines. Some market observers speculated that AI-driven biological discoveries could eventually affect the biotechnology industry. However, the timing of these declines does not prove that Anthropic’s announcement alone caused them, nor does the preliminary ART finding establish a threat to existing gene-editing treatments.

5. Who is Mario Rodríguez Mestre, and why does he challenge Anthropic’s discovery?

Mario Rodríguez Mestre is a University of Copenhagen researcher who claimed that his unpublished doctoral research had described the same or closely related biological patterns before Anthropic’s announcement. He also raised questions about the extent of human guidance behind Claude’s work and information he had previously shared with the AI models. However, the available evidence does not conclusively establish scientific priority, direct influence on the result, or the precise relationship between the two research efforts.

6. Has Anthropic’s ART discovery been scientifically verified?

The findings have been shared in a preprint, but the article does not establish that the research has completed peer review. Independent researchers have described the findings as potentially interesting while emphasizing that further experiments are needed. Reproducibility, independent validation, and a clearer understanding of ART’s biological function will be essential to determining the discovery’s scientific importance.

7. What are the future prospects of ART and AI-driven biological research?

ART could become an important subject of biological research if further studies establish its function and reveal useful applications. Researchers must investigate its molecular mechanisms, reproduce the reported results, and determine whether it has practical value in biotechnology or gene editing. The controversy also highlights the importance of human oversight, scientific attribution, research-data provenance, and responsible communication when AI contributes to scientific discoveries. Until stronger evidence emerges, ART should be regarded as a promising research lead rather than a proven gene-editing breakthrough.